<DOC>
	<DOCNO>NCT02441764</DOCNO>
	<brief_summary>This PMS observe safety profile Halaven normal clinical practice setting .</brief_summary>
	<brief_title>Halaven Post-Marketing Surveillance ( PMS )</brief_title>
	<detailed_description />
	<criteria>Participants prescribe Halaven per approve prescribe information Halaven enrol study . This study conduct complete surveillance method ; participant meet inclusion/exclusion criterion administrate Halaven first time conclusion agreement enrol consent . Participants meet follow criterion eligible inclusion study : 1 . Participants follow indication : Participants locally advance metastatic breast cancer previously receive least two chemotherapeutic regimen include anthracycline taxane . 2 . Participants verbal write consent use personal medical information . Investigators refer indication regard inclusion criterion . 1 . Hypersensitivity active substance excipients 2 . Breast feed 3 . Pregnancy Investigators refer indication contraindication regard exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Halaven</keyword>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>locally advanced metastatic breast cancer</keyword>
</DOC>